These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. McFadyen JD; Stevens H; Peter K Circ Res; 2020 Jul; 127(4):571-587. PubMed ID: 32586214 [TBL] [Abstract][Full Text] [Related]
6. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. Bikdeli B; Madhavan MV; Jimenez D; Chuich T; Dreyfus I; Driggin E; Nigoghossian C; Ageno W; Madjid M; Guo Y; Tang LV; Hu Y; Giri J; Cushman M; Quéré I; Dimakakos EP; Gibson CM; Lippi G; Favaloro EJ; Fareed J; Caprini JA; Tafur AJ; Burton JR; Francese DP; Wang EY; Falanga A; McLintock C; Hunt BJ; Spyropoulos AC; Barnes GD; Eikelboom JW; Weinberg I; Schulman S; Carrier M; Piazza G; Beckman JA; Steg PG; Stone GW; Rosenkranz S; Goldhaber SZ; Parikh SA; Monreal M; Krumholz HM; Konstantinides SV; Weitz JI; Lip GYH; J Am Coll Cardiol; 2020 Jun; 75(23):2950-2973. PubMed ID: 32311448 [TBL] [Abstract][Full Text] [Related]
7. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?]. Nisole S; Saulnier A; Gatignol A Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548 [No Abstract] [Full Text] [Related]
8. Treatments for COVID-19: emerging drugs against the coronavirus. Potì F; Pozzoli C; Adami M; Poli E; Costa LG Acta Biomed; 2020 May; 91(2):118-136. PubMed ID: 32420936 [TBL] [Abstract][Full Text] [Related]
9. Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology. Vivas D; Roldán V; Esteve-Pastor MA; Roldán I; Tello-Montoliu A; Ruiz-Nodar JM; Cosín-Sales J; Gámez JM; Consuegra L; Ferreiro JL; Marín F; Rev Esp Cardiol (Engl Ed); 2020 Sep; 73(9):749-757. PubMed ID: 32694078 [TBL] [Abstract][Full Text] [Related]
10. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study]. Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014 [TBL] [Abstract][Full Text] [Related]
13. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial. Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611 [TBL] [Abstract][Full Text] [Related]
14. Severe COVID-19 disease and thromboinflammation. Jerjes-Sánchez C Arch Cardiol Mex; 2020; 90(3):257-258. PubMed ID: 32952161 [No Abstract] [Full Text] [Related]
15. Silencing of immune activation with methotrexate in patients with COVID-19. Safavi F; Nath A J Neurol Sci; 2020 Aug; 415():116942. PubMed ID: 32471659 [No Abstract] [Full Text] [Related]
16. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity. Schijns V; Lavelle EC Eur J Immunol; 2020 Jul; 50(7):932-938. PubMed ID: 32438473 [TBL] [Abstract][Full Text] [Related]
17. Pathogenesis and Treatment Strategies of COVID-19-Related Hypercoagulant and Thrombotic Complications. Haimei MA Clin Appl Thromb Hemost; 2020; 26():1076029620944497. PubMed ID: 32722927 [TBL] [Abstract][Full Text] [Related]
18. A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus? Oscanoa TJ; Romero-Ortuno R; Carvajal A; Savarino A Int J Antimicrob Agents; 2020 Sep; 56(3):106078. PubMed ID: 32629115 [TBL] [Abstract][Full Text] [Related]
19. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). Marietta M; Ageno W; Artoni A; De Candia E; Gresele P; Marchetti M; Marcucci R; Tripodi A Blood Transfus; 2020 May; 18(3):167-169. PubMed ID: 32281926 [No Abstract] [Full Text] [Related]
20. The Multiple Effects of SGLT2 Inhibitors Suggest Potential Benefit in COVID-19 Patients. Soni S; Dyck JRB Can J Cardiol; 2020 Oct; 36(10):1691.e3. PubMed ID: 32717278 [No Abstract] [Full Text] [Related] [Next] [New Search]